Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
Ohkawa K, Nakabori T, Mukai K, Kozumi K, Urabe M, Kai Y, Takada R, Ikezawa K, Yamaguchi Y, Nagao T, Enomoto H, Tachiki H, Higuchi A, Watanabe N, Nakayama T. Ohkawa K, et al. Among authors: tachiki h. PLoS One. 2024 Oct 24;19(10):e0311930. doi: 10.1371/journal.pone.0311930. eCollection 2024. PLoS One. 2024. PMID: 39446769 Free PMC article.
Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay.
Ishikawa R, Saito K, Tachiki H, Goda R, Arai K, Shimizu H, Andou T, Takahara K, Uchiyama H, Nitta SI, Kakehi M, Hayashi K, Katagiri N, Kojima K, Fujita H, Tsuchinaga K, Saito Y. Ishikawa R, et al. Among authors: tachiki h. Bioanalysis. 2023 Feb;15(4):207-218. doi: 10.4155/bio-2022-0240. Epub 2023 Mar 24. Bioanalysis. 2023. PMID: 36961372
Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression.
Sakai N, Kamimura K, Miyamoto H, Ko M, Nagoya T, Setsu T, Sakamaki A, Yokoo T, Kamimura H, Soki H, Tokunaga A, Inamine T, Nakashima M, Enomoto H, Kousaka K, Tachiki H, Ohyama K, Terai S. Sakai N, et al. Among authors: tachiki h. J Gastroenterol. 2023 Jan;58(1):53-68. doi: 10.1007/s00535-022-01929-w. Epub 2022 Oct 27. J Gastroenterol. 2023. PMID: 36301364
Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Shindo T, Maehana T, Tanaka T, Hashimoto K, Kobayashi K, Takahashi A, Hotta H, Kunishima Y, Taguchi K, Tachiki H, Ito N, Matsukawa M, Kato R, Miyamoto S, Hinotsu S, Masumori N. Shindo T, et al. Among authors: tachiki h. Int J Urol. 2022 Sep;29(9):1010-1016. doi: 10.1111/iju.14941. Epub 2022 Jun 2. Int J Urol. 2022. PMID: 35654444
Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
Shindo T, Hashimoto K, Tanaka T, Taguchi K, Takahashi A, Itoh N, Okada M, Hotta H, Kunishima Y, Hirose T, Matsukawa M, Tachiki H, Kato R, Hinotsu S, Masumori N. Shindo T, et al. Among authors: tachiki h. Int J Urol. 2021 Nov;28(11):1136-1142. doi: 10.1111/iju.14657. Epub 2021 Aug 3. Int J Urol. 2021. PMID: 34342065
54 results